| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/15/2002 | EP1204655A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 05/15/2002 | EP1204650A1 Substituted 2-arylbenzazole compounds and their use as antitumour agents |
| 05/15/2002 | EP1204649A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
| 05/15/2002 | EP1204646A1 1,4,5,6 -tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 05/15/2002 | EP1204645A2 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 05/15/2002 | EP1204626A1 Ether compounds, compositions, and uses thereof |
| 05/15/2002 | EP1204430A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 05/15/2002 | EP1204429A2 Sustained release formulation of a peptide |
| 05/15/2002 | EP1204423A1 Therapeutic antibody against muc-1 antigen and methods for their use |
| 05/15/2002 | EP1204418A1 Compositions containing muscle-derived active agents |
| 05/15/2002 | EP1204417A2 Parenteral cisplatin emulsion |
| 05/15/2002 | EP1204412A2 Use of etodolac to treat cancer |
| 05/15/2002 | EP1204411A1 Apicidin-derived cyclic tetrapeptides |
| 05/15/2002 | EP1204407A2 Implantable active ingredient depot |
| 05/15/2002 | EP1147186A4 In vitro activated gamma delta lymphocytes |
| 05/15/2002 | EP1102594B1 Use of sodium chloride to reduce the gastrointestinal toxicity of camptothecin derivatives |
| 05/15/2002 | EP1082028B1 Matthiola seed oil, mixtures containing it and use thereof |
| 05/15/2002 | EP1071745A4 Process for synthesizing cox-2 inhibitors |
| 05/15/2002 | EP1054686B1 Pharmaceutical formulation of a didemnin compound |
| 05/15/2002 | EP1049694B1 Derivatives of benzoxadiazoles, benzothiadiazoles, benzotriazoles and quinoxalines |
| 05/15/2002 | EP0729460B1 Substituted 5-ring heterocycles, their preparation and their use |
| 05/15/2002 | EP0617623B1 Transdermally administered system containing acetylsalicylic acid for thrombosis therapy |
| 05/15/2002 | EP0610499B1 Proteoglycan(g 009) effective in enhancing antitumor immunity |
| 05/15/2002 | CN1349541A L-ribo-LNA analogues |
| 05/15/2002 | CN1349538A Cyclocarbamate and cyclic amide derivatives |
| 05/15/2002 | CN1349537A Cyclic urea and cyclic amide derivatives |
| 05/15/2002 | CN1349536A Thienopyrimidine compounds, their production and use |
| 05/15/2002 | CN1349534A 6-alkenyl-, 6-alkinyl-and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
| 05/15/2002 | CN1349531A Cyanopyrroles as progesterone receptor agonists |
| 05/15/2002 | CN1349528A Pyrimidine compounds |
| 05/15/2002 | CN1349523A Novel lipoic acid derivatives, their prepn., and pharmaceutical compositions containing them |
| 05/15/2002 | CN1349518A 2,1-benzisothiazoline 2,2-dioxydes |
| 05/15/2002 | CN1349517A Cyclocarbamate derivatives as progesterone receptor modulators |
| 05/15/2002 | CN1349516A Cyclothiocarbamate derivatives as progesterone receptor modulators |
| 05/15/2002 | CN1349511A Benzimidazolrone and analogues, and the use as ligand of progesterone |
| 05/15/2002 | CN1349510A Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors |
| 05/15/2002 | CN1349508A Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| 05/15/2002 | CN1349500A 3,3-substituted indoline derivatives |
| 05/15/2002 | CN1349499A Thio-oxindole derivatives |
| 05/15/2002 | CN1349496A Caspase inhibitors and the use thereof |
| 05/15/2002 | CN1349423A Composition comprising tramadol aterial and a selective cox-2 inhibitor drug |
| 05/15/2002 | CN1349413A Contraceptive compositions containing quinazolinone and benzoxazine derivatives |
| 05/15/2002 | CN1349412A Contraceptive compositions containing cyclic urea and amide derivatives |
| 05/15/2002 | CN1349406A Combined preparations comprising morpholine anthracyclines and anticancer agent |
| 05/15/2002 | CN1348983A Kenrel oil composite extracted from plant kernel and its extraction process and application |
| 05/15/2002 | CN1348818A Leukemia treating granule capable of being used to replace chemotherapy and marrow transplantation |
| 05/15/2002 | CN1348817A Production process of natural anticarcinogen |
| 05/15/2002 | CN1348784A Kangzhi as one orally taken and externally applied medicine |
| 05/15/2002 | CN1348778A Chinese medicine prepn for treating AIDS, cancer, hepatitis, diabetes and angiopathy |
| 05/15/2002 | CN1348763A Medicine composite for preventing or treaitng diseases relating to IL-12 over growth |
| 05/15/2002 | CN1084740C Angiogensis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives |
| 05/15/2002 | CN1084626C Granulated prepn for promoting blood-circulation and removing blood stasis |
| 05/15/2002 | CN1084615C Application of tea component in prepn. of pharmaceuticals |
| 05/14/2002 | US6388092 Antitumor agent |
| 05/14/2002 | US6387950 4((4-chloro-3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro -naphathalene-2-carbonyl)-amino)-2,6-difluoro-benzoic acid or its esters or salts used as agonists of alpha-retinoid receptors (=raralpha) |
| 05/14/2002 | US6387946 Methods for treating pathological conditions of abnormal cell proliferation |
| 05/14/2002 | US6387932 Somatostatin agonists |
| 05/14/2002 | US6387927 Water solubility |
| 05/14/2002 | US6387926 Inhibitors of farnesyl protein transferase |
| 05/14/2002 | US6387923 Antiproliferative agents; anticancer agents |
| 05/14/2002 | US6387919 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 05/14/2002 | US6387911 Pyrazinone thrombin inhibitors |
| 05/14/2002 | US6387905 Compounds useful for inhibition of farnesyl protein transferase |
| 05/14/2002 | US6387900 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| 05/14/2002 | US6387899 Antiserotonine agents; antidepressants |
| 05/14/2002 | US6387895 Bone disorders; cardiovascular disorders |
| 05/14/2002 | US6387892 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
| 05/14/2002 | US6387888 Prostate cancer |
| 05/14/2002 | US6387883 Method for the prevention and treatment of cachexia and anorexia |
| 05/14/2002 | US6387875 Method of use for murine leukaemia inhibitory factor-binding protein (mLBP) |
| 05/14/2002 | US6387701 Method of identifying tumor antigens that elicit a T-cell response |
| 05/14/2002 | US6387698 Polyclonal antiserum produced by immunzing animal with tumor rejection antigen precursor |
| 05/14/2002 | US6387682 Amino acid sequence of polypeptide with cysteine protease activity; treatment of bone disorders such as osteoporosis; anticarcinogenic agents; antitumor agents; antimetastasis agents |
| 05/14/2002 | US6387663 Fusion protein of collagen binding domain and angiogenesis modulating domain; treatment of cardiovascular disorders; antiischemic agents |
| 05/14/2002 | US6387657 Amino acid sequence of wnt-1-induced secreted protein; anticarcinogenic agents; antitumor agents; treatment of arteriosclerosis; diagnosis of related disorders |
| 05/14/2002 | US6387396 In gene therapy and in in vitro and in vivo transfection |
| 05/14/2002 | US6387374 Complex consists essentially of a heat shock protein noncovalently bound to an antigenic molecule |
| 05/14/2002 | US6387371 Specifically binds to an extracellular domain of the her2 receptor in an amount effective to inhibit growth of cancer cells |
| 05/14/2002 | CA2267186C Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| 05/14/2002 | CA2260898C Phosphinate based inhibitors of matrix metalloproteases |
| 05/14/2002 | CA2086323C Functionally active selectin-derived peptides and ligand for gmp-140 |
| 05/14/2002 | CA2075876C Arylethylamines derivatives, process for their preparation and pharmaceutical compositions holding same |
| 05/10/2002 | WO2002037113A2 Clinical and functional validation of targets from disseminated cancer cells |
| 05/10/2002 | WO2002036816A2 Method of determining susceptibility to diseases |
| 05/10/2002 | WO2002036807A2 Compositions and methods relating to breast specific genes and proteins |
| 05/10/2002 | WO2002036792A2 Dna expression vectors |
| 05/10/2002 | WO2002036783A2 Regulation of human histone deacetylase |
| 05/10/2002 | WO2002036771A2 Imaging, diagnosis and treatment of disease |
| 05/10/2002 | WO2002036761A2 Compositions and methods for the diagnosis of cancer |
| 05/10/2002 | WO2002036750A2 T-cells specifically recognizing minor histocompatibility antigen(s) and uses thereof for eliminating target cells |
| 05/10/2002 | WO2002036741A2 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/10/2002 | WO2002036733A2 Cd36 as a heat shock protein receptor and uses thereof |
| 05/10/2002 | WO2002036627A2 Interferons, uses and compositions related thereto |
| 05/10/2002 | WO2002036625A2 Prokineticin polypeptides, related compositions and methods |
| 05/10/2002 | WO2002036619A1 A new polypeptide-human glycoprotein 42 and the polynucleotide encoding it |
| 05/10/2002 | WO2002036611A2 Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| 05/10/2002 | WO2002036607A1 Phenanthridine derivatives and antitumoral medicaments containing phenanthridine |
| 05/10/2002 | WO2002036599A1 Thieno[2,3-c]isoquinolines for use as inhibitors of parp |
| 05/10/2002 | WO2002036597A1 Tricyclic derivatives of indole with antiangiogenic activity |
| 05/10/2002 | WO2002036592A1 Remedies for arachidonic acid-induced skin diseases |